Literature DB >> 15762873

Aspirin down-regulates tryptophan degradation in stimulated human peripheral blood mononuclear cells in vitro.

K Schroecksnadel1, C Winkler, B Wirleitner, H Schennach, D Fuchs.   

Abstract

Acetylsalicylic acid (aspirin) is one of the most widely used drugs worldwide, due mainly to its broad therapeutic spectrum with anti-inflammatory, antipyretic, antithrombotic and analgesic effects. However, the exact mechanisms by which aspirin influences inflammation, pain and immune system activation are only partly understood. Within activation of the cellular immune system, Th1-type cytokine interferon (IFN)-gamma induces enzyme indoleamine-2,3-dioxygenase (IDO) which converts tryptophan to kynurenine. In parallel, IFN-gamma induces enzyme GTP-cyclohydrolase I, which gives rise to neopterin production by activated human macrophages. Similarly, tryptophan degradation and neopterin formation increase during several disease states involving Th1-type immune activation. Using stimulated human peripheral blood mononuclear cells (PBMC), the effect of aspirin on tryptophan degradation and neopterin production was investigated. Stimulation of PBMC with mitogens concanavalin A, phytohaemagglutinin and pokeweed mitogen induced significant tryptophan catabolism as was reflected by a decline in tryptophan levels and a parallel increase in kynurenine concentrations compared with unstimulated cells. In parallel, neopterin production was enhanced. Treatment of stimulated PBMC with increasing doses of 1-5 mM aspirin significantly decreased stimulation-induced tryptophan degradation and neopterin production as well. All the effects of aspirin were dose-dependent. The parallel influence of aspirin on both biochemical pathways implies that there was no direct inhibitory effect of aspirin on IDO; rather, it inhibits production of IFN-gamma in mitogen-treated PBMC. The influence of aspirin on biochemical pathways induced by IFN-gamma may represent an important part of its broad pharmacological effect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15762873      PMCID: PMC1809338          DOI: 10.1111/j.1365-2249.2005.02746.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage.

Authors:  D N Muller; V Heissmeyer; R Dechend; F Hampich; J K Park; A Fiebeler; E Shagdarsuren; J Theuer; M Elger; B Pilz; V Breu; K Schroer; D Ganten; R Dietz; H Haller; C Scheidereit; F C Luft
Journal:  FASEB J       Date:  2001-08       Impact factor: 5.191

2.  Trends in rheumatic disease: update on new diagnostic and treatment strategies.

Authors:  B F Mandell
Journal:  Cleve Clin J Med       Date:  2001-05       Impact factor: 2.321

Review 3.  Cyclooxygenase-independent actions of cyclooxygenase inhibitors.

Authors:  I Tegeder; J Pfeilschifter; G Geisslinger
Journal:  FASEB J       Date:  2001-10       Impact factor: 5.191

4.  Simultaneous measurement of serum tryptophan and kynurenine by HPLC.

Authors:  B Widner; E R Werner; H Schennach; H Wachter; D Fuchs
Journal:  Clin Chem       Date:  1997-12       Impact factor: 8.327

Review 5.  Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases?

Authors:  L Adorini; J C Guéry; S Trembleau
Journal:  Autoimmunity       Date:  1996       Impact factor: 2.815

Review 6.  Pro- and anti-inflammatory cytokines in rheumatoid arthritis.

Authors:  P Isomäki; J Punnonen
Journal:  Ann Med       Date:  1997-12       Impact factor: 4.709

7.  Prevention of allogeneic fetal rejection by tryptophan catabolism.

Authors:  D H Munn; M Zhou; J T Attwood; I Bondarev; S J Conway; B Marshall; C Brown; A L Mellor
Journal:  Science       Date:  1998-08-21       Impact factor: 47.728

8.  Decreased IL-12 production and Th1 cell development by acetyl salicylic acid-mediated inhibition of NF-kappaB.

Authors:  D Mazzeo; P Panina-Bordignon; H Recalde; F Sinigaglia; D D'Ambrosio
Journal:  Eur J Immunol       Date:  1998-10       Impact factor: 5.532

9.  Decreased plasma tryptophan in pregnancy.

Authors:  H Schröcksnadel; G Baier-Bitterlich; O Dapunt; H Wachter; D Fuchs
Journal:  Obstet Gynecol       Date:  1996-07       Impact factor: 7.661

10.  Inhibition of T cell proliferation by macrophage tryptophan catabolism.

Authors:  D H Munn; E Shafizadeh; J T Attwood; I Bondarev; A Pashine; A L Mellor
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

View more
  16 in total

Review 1.  Minireview: Gut microbiota: the neglected endocrine organ.

Authors:  Gerard Clarke; Roman M Stilling; Paul J Kennedy; Catherine Stanton; John F Cryan; Timothy G Dinan
Journal:  Mol Endocrinol       Date:  2014-06-03

Review 2.  Disturbed tryptophan metabolism in cardiovascular disease.

Authors:  H Mangge; I Stelzer; E Z Reininghaus; D Weghuber; T T Postolache; D Fuchs
Journal:  Curr Med Chem       Date:  2014-06       Impact factor: 4.530

Review 3.  Irritable bowel syndrome: a microbiome-gut-brain axis disorder?

Authors:  Paul J Kennedy; John F Cryan; Timothy G Dinan; Gerard Clarke
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

4.  In vitro testing for anti-inflammatory properties of compounds employing peripheral blood mononuclear cells freshly isolated from healthy donors.

Authors:  M Jenny; M Klieber; D Zaknun; S Schroecksnadel; K Kurz; M Ledochowski; H Schennach; Dietmar Fuchs
Journal:  Inflamm Res       Date:  2010-08-26       Impact factor: 4.575

5.  Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study.

Authors:  Meagan O'Brien; Emilie Montenont; Liang Hu; Michael A Nardi; Vanessa Valdes; Michael Merolla; Gabrielle Gettenberg; Karen Cavanagh; Judith A Aberg; Nina Bhardwaj; Jeffrey S Berger
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07-01       Impact factor: 3.731

Review 6.  IDO and TDO as a potential therapeutic target in different types of depression.

Authors:  Yanjie Qin; Nanxi Wang; Xinlin Zhang; Xuemei Han; Xuejia Zhai; Yongning Lu
Journal:  Metab Brain Dis       Date:  2018-07-16       Impact factor: 3.584

Review 7.  Antioxidants, inflammation and cardiovascular disease.

Authors:  Harald Mangge; Kathrin Becker; Dietmar Fuchs; Johanna M Gostner
Journal:  World J Cardiol       Date:  2014-06-26

Review 8.  Tryptophan Metabolism in Allergic Disorders.

Authors:  Johanna M Gostner; Katrin Becker; Heinz Kofler; Barbara Strasser; Dietmar Fuchs
Journal:  Int Arch Allergy Immunol       Date:  2016-05-04       Impact factor: 2.749

9.  Antimalarial drug chloroquine counteracts activation of indoleamine (2,3)-dioxygenase activity in human PBMC.

Authors:  Johanna M Gostner; Sebastian Schröcksnadel; Kathrin Becker; Marcel Jenny; Harald Schennach; Florian Uberall; Dietmar Fuchs
Journal:  FEBS Open Bio       Date:  2012-08-17       Impact factor: 2.693

10.  Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort.

Authors:  Gerard Clarke; Peter Fitzgerald; John F Cryan; Eugene M Cassidy; Eamonn M Quigley; Timothy G Dinan
Journal:  BMC Gastroenterol       Date:  2009-01-20       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.